Role of ventral hippocampal NMDA receptors in anxiolytic-like effect of morphine

Physiology and Behavior

Volumn 101, Issue 5, 2010, Pages 608-613

  Motevasseli, Tahmineh ^a   Rezayof, Ameneh ^b   Zarrindast, Mohammad Reza ^c,d,e   Nayer Nouri, Touraj ^e  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e INSTITUTE FOR RESEARCH IN FUNDAMENTAL SCIENCES IPM   (Iran)

Author keywords

D AP5; Elevated plus maze; Mouse (mice); NMDA; Ventral hippocampus

Indexed keywords

D AP5; MORPHINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HIPPOCAMPUS; LOCOMOTION; LOW DRUG DOSE; MALE; MAZE TEST; MICROINJECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

2-AMINO-5-PHOSPHONOVALERATE; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; MICE; MICROINJECTIONS; MORPHINE; MOTOR ACTIVITY; N-METHYLASPARTATE; NARCOTICS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 78149266341     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2010.09.013     Document Type: Article

References (37)

1. Bergink V., van Megen H.J., Westenberg H.G. Glutamate and anxiety. Eur Neuropsychopharmacol 2004, 14:175-183.
2. Kew J.N., Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 2005, 179:4-29.
3. Cotman C.W., Monaghan D.T. Anatomical organization of excitatory amino acid receptors and their properties. Adv Exp Med Biol 1986, 203:237-252.
4. Erreger K., Chen P.E., Wyllie D.J., Traynelis S.F. Glutamate receptor gating. Crit Rev Neurobiol 2004, 16:187-224.
5. Cortese B.M., Phan K.L. The role of glutamate in anxiety and related disorders. CNS Spectr 2005, 10:820-830.
6. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R. Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996, 29:23-26.
7. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990, 185:1-10.
8. Przegalinski E., Tatarczynska E., Chojnacka-Wojcik E. Anxiolytic- and antidepressant-like effects of an antagonist at glycineB receptors. Pol J Pharmacol 1998, 50:349-354.
9. Bannerman D.M., Rawlins J.N., McHugh S.B., Deacon R.M., Yee B.K., Bast T., et al. Regional dissociations within the hippocampus-memory and anxiety. Neurosci Biobehav Rev 2004, 28:273-283.
10. Alves S.H., Pinheiro G., Motta V., Landeira-Fernandez J., Cruz A.P. Anxiogenic effects in the rat elevated plus-maze of 5-HT(2C) agonists into ventral but not dorsal hippocampus. Behav Pharmacol 2004, 15:37-43.
11. Kjelstrup K.G., Tuvnes F.A., Steffenach H.A., Murison R., Moser E.I., Moser M.B. Reduced fear expression after lesions of the ventral hippocampus. Proc Natl Acad Sci USA 2002, 99:10825-10830.
12. McHugh S.B., Deacon R.M., Rawlins J.N., Bannerman D.M. Amygdala and ventral hippocampus contribute differentially to mechanisms of fear and anxiety. Behav Neurosci 2004, 118:63-78.
13. Pandis C., Sotiriou E., Kouvaras E., Asprodini E., Papatheodoropoulos C., Angelatou F. Differential expression of NMDA and AMPA receptor subunits in rat dorsal and ventral hippocampus. Neuroscience 2006, 140:163-175.
14. Zarrindast M.R., Babapoor-Farrokhran S., Babapoor-Farrokhran S., Rezayof A. Involvement of opioidergic system of the ventral hippocampus, the nucleus accumbens or the central amygdala in anxiety-related behavior. Life Sci 2008, 82:1175-1181.
15. Rezayof A., Hosseini S.S., Zarrindast M.R. Effects of morphine on rat behaviour in the elevated plus maze: the role of central amygdala dopamine receptors. Behav Brain Res 2009, 202:171-178.
16. Barkus C., McHugh S.B., Sprengel R., Seeburg P.H., Rawlins J.N., Bannerman D.M. Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. Eur J Pharmacol 2010, 626:49-56.
17. Rezayof A., Golhasani-Keshtan F., Haeri-Rohani A., Zarrindast M.R. Morphine-induced place preference: involvement of the central amygdala NMDA receptors. Brain Res 2007, 1133:34-41.
18. Zarrindast M.R., Lashgari R., Rezayof A., Motamedi F., Nazari-Serenjeh F. NMDA receptors of dorsal hippocampus are involved in the acquisition, but not in the expression of morphine-induced place preference. Eur J Pharmacol 2007, 568:192-198.
19. Zarrindast M.R., Jafari-Sabet M., Rezayat M., Djahanguiri B., Rezayof A. Involvement of NMDA receptors in morphine state-dependent learning in mice. Int J Neurosci 2006, 116:731-743.
20. Jafari-Sabet M., Zarrindast M.R., Rezayat M., Rezayof A., Djahanguiri B. The influence of NMDA receptor agonist and antagonist on morphine state-dependent memory of passive avoidance in mice. Life Sci 2005, 78:157-163.
21. Rodgers R.J., Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 1997, 21:801-810.
22. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2001, Academic Press. 2nd Ed.
23. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
24. Koks S., Soosaar A., Voikar V., Bourin M., Vasar E. BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze. Neuropeptides 1999, 33:63-69.
25. Sasaki K., Fan L.W., Tien L.T., Ma T., Loh H.H., Ho I.K. The interaction of morphine and gamma-aminobutyric acid (GABA)ergic systems in anxiolytic behavior: using mu-opioid receptor knockout mice. Brain Res Bull 2002, 57:689-694.
26. Zhang H.T., Xu Z.M., Luo Z.P., Qin B.Y. Anxiogenic effect of naltrexone in social interaction test in rats. Zhongguo Yao Li Xue Bao 1996, 17:314-317.
27. Liu P., Smith P.F., Darlington C.L. Glutamate receptor subunits expression in memory-associated brain structures: regional variations and effects of aging. Synapse 2008, 62:834-841.
28. Johnson P.I., Parente M.A., Stellar J.R. NMDA-induced lesions of the nucleus accumbens or the ventral pallidum increase the rewarding efficacy of food to deprived rats. Brain Res 1996, 722:109-117.
29. Winn P., Clark J.M., Clark A.J., Parker G.C. NMDA lesions of lateral hypothalamus enhance the acquisition of schedule-induced polydipsia. Physiol Behav 1992, 52:1069-1075.
30. Rezvanfard M., Zarrindast M.R., Bina P. Role of ventral hippocampal GABA(A) and NMDA receptors in the anxiolytic effect of carbamazepine in rats using the elevated plus maze test. Pharmacology 2009, 84:356-366.
31. Adamec R.E., Burton P., Shallow T., Budgell J. NMDA receptors mediate lasting increases in anxiety-like behavior produced by the stress of predator exposure-implications for anxiety associated with posttraumatic stress disorder. Physiol Behav 1999, 65:723-737.
32. Padovan C.M., Del Bel E.A., Guimaraes F.S. Behavioral effects in the elevated plus maze of an NMDA antagonist injected into the dorsal hippocampus: influence of restraint stress. Pharmacol Biochem Behav 2000, 67:325-330.
33. Sepehrizadeh Z., Sahebgharani M., Ahmadi S., Shapourabadi M.B., Bozchlou S.H., Zarrindast M.R. Morphine-induced behavioral sensitization increased the mRNA expression of NMDA receptor subunits in the rat amygdala. Pharmacology 2008, 81:333-343.
34. Lydiard R.B. The role of GABA in anxiety disorders. J Clin Psychiatry 2003, 64(Suppl 3):21-27.
35. Tao R., Auerbach S.B. GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther 2002, 303:704-710.
36. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991, 251:85-87.
37. Nascimento Hackl L.P., Carobrez A.P. Distinct ventral and dorsal hippocampus AP5 anxiolytic effects revealed in the elevated plus-maze task in rats. Neurobiol Learn Mem 2007, 88:177-185.